Evidence map›Paper›PMID 41707107›Full record

ArticleBlood advances2026

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Manali KamdarDivision of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO.ORCID 0000-0002-1930-152X
Scott R SolomonNorthside Hospital Cancer Institute, Atlanta, GA.
Jon ArnasonBeth Israel Deaconess Medical Center, Boston, MA.
Patrick B JohnstonMayo Clinic, Rochester, MN.
Bertram GlassHelios Klinikum Berlin-Buch, Berlin, Germany.
Veronika BachanovaDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Sami IbrahimiUniversity of Oklahoma Stephenson Cancer Center, Oklahoma City, OK.
Stephan MielkeKarolinska Comprehensive Cancer Center, Karolinska Institutet and University Hospital, Stockholm, Sweden.ORCID 0000-0002-8325-9215
Pim MutsaersErasmus University Medical Center, Rotterdam, The Netherlands.
Francisco Hernandez-IlizaliturriRoswell Park Comprehensive Cancer Center, Buffalo, NY.
Koji IzutsuNational Cancer Center Hospital, Tokyo, Japan.
Franck MorschhauserGroupe de Recherche sur les forms Injectables et les Technologies Associées, Centre Hospitalier Universitaire de Lille, Lille, France.
Matthew LunningUniversity of Nebraska Medical Center, Omaha, NE.
Vincent RibragInstitut Gustave Roussy, Villejuif, France.ORCID 0000-0002-5221-353X
Yi LinMayo Clinic, Rochester, MN.
Rashmi BhatnagarSyneos Health, Gurugram, India.
Robert BraunBristol Myers Squibb, Boudry, Switzerland.
Sandrine MontheardBristol Myers Squibb, Boudry, Switzerland.
Jeremy S AbramsonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-8467-9257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41707107
PMCPMC13138141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.